ArticlePituitary2025
Microbiome and metabolic disorder in prolactinoma: intrinsic gender differences and extrinsic therapy effects.
Article in Pituitary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Hyperprolactinemia and Brain Health: Exploring the Gut-Brain Axis and Therapeutic Strategies.Molecular neurobiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
Abstract
purposeProlactinoma is the most common functional pituitary adenoma. As for gender disparity in the metabolic state, males tended to have higher rates of metabolic disorders, while treatment with dopamine agonists enabled partial improvement in metabolic disorders. Oral medication used to be the first-line treatment option; thus, the efficacy of dopamine receptor agonists is linked to the intestinal microenvironment. The gut microbiome is known to interact with host physiology and metabolic profile. Therefore, it is necessary to uncover the linkages between the alteration of gut microbiota and prolactinoma.
methods28 Patients diagnosed with prolactinoma and 31 healthy controls were included. Fecal samples were collected for 16 S rRNA gene sequencing and metagenomic sequencing to identify featured intestinal microflora between patients and healthy individuals, as well as to examine how gender and dopamine agonists affect the gut microbiome’s structure.
resultsAgathobacter, Blautia, Dorea, Fusicatenibacter, and Mediterraneibacter were prominent in the PRLoma group. Bilophila wadsworthia, Clostridium sp. CAG:7, Megasphaera elsdenii, and Mycoplasma sp. CAG:472 were independently associated with metabolic disorders in male patients. This metabolic regulatory effect may result from the levels of Xylose, the glycine to serine ratio, N2-acetyl, N6, N6-dimethyllysine levels, and the cholesterol to oleoyl-linoleoyl-glycerol (18:1 to 18:2) ratio in plasma. Furthermore, administering dopamine agonists reduced harmful species such as Fusobacterium mortiferum, Bacteroides fragilis, and Ruminococcus biciculans, potentially contributing to an improved metabolic status.
conclusionsPatients with prolactinoma have different intestinal flora than healthy individuals. In addition to the occurrence of prolactinoma and concomitant serum prolactin excess, the gender effect and administration of dopamine agonists are also involved in regulating intestinal microbiota and the metabolic status of the host.
Indexed as
Identifiers
40608175What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.